Back to NewsletterNewsletter

    Tirzepatide's early epigenetic signal: what it does and doesn't show

    What changed on peakhuman.ai this week, with the caveats attached.

    Nov 9, 20264 min read

    A note from Dr. Goel

    Four evidence pages were updated this week, each with a caveat worth hearing before a patient asks. Everything below summarizes published research and is not a recommendation to start anything.

    — Dr. Sanjeev Goel

    📊 Tirzepatide (updated Nov 8)

    The page now covers a Lilly sub-study presented at ARDD 2026: an unpublished, single-arm epigenetic analysis of 71 SURMOUNT-5 participants. Only 2 of 15 epigenetic clocks reached significance; DunedinPACE moved from a median of 1.13 to 1.08. It is an early, commercial, non-peer-reviewed signal and does not show tirzepatide slows aging.

    Anchor on the randomized data: SURMOUNT-5 (NEJM, 2025; 751 adults with obesity without diabetes, 72 weeks): -20.2% vs -13.7% weight change with semaglutide (p<0.001); open-label, Lilly-sponsored.

    ⏱️ Intermittent fasting (updated Nov 3)

    2025 BMJ network meta-analysis (Semnani-Azad et al.; 99 RCTs, 6,582 adults): IF and continuous energy restriction gave similarly small weight reductions; alternate-day fasting beat continuous restriction by 1.29 kg, below the authors' 2 kg clinical threshold.

    Plus a 2026 Diabetologia meta-analysis of time-restricted eating in prediabetes/T2D (10 RCTs, 599 adults): HbA1c improved significantly only in prediabetes.

    🧪 Astaxanthin (reviewed Nov 6)

    A 2026 meta-analysis pooling 9 RCTs (403 adults with prediabetes/T2D) reports improvements in fasting glucose, lipids and HbA1c; HOMA-IR and body weight unchanged. GRADE certainty low to very low; no large hard-outcome trials; a 2020 meta-analysis found no association with fasting glucose or HbA1c.

    🧠 Low-dose lithium (reviewed Nov 7)

    No completed human trial of lithium orotate itself. Closest human data is LATTICE (JAMA Neurology 2026; 80 older adults with MCI, lithium carbonate): missed co-primary endpoints, but delayed-recall decline 0.73 vs 1.42 points/year with placebo (nominal P=0.05). Contraindications listed on the page include kidney disease, thyroid disease, pregnancy and concurrent prescription lithium.

    Tirzepatide's metabolic and cardiovascular evidence is strong; the epigenetic-clock result is a company-presented single-arm sub-analysis in which 2 of 15 clocks moved. Keep the conversation on indications with randomized evidence and tell patients the aging data is early and unreviewed.

    Important disclaimer

    This newsletter is for educational purposes for licensed healthcare professionals and is not medical advice. It summarizes published research; it does not recommend, endorse or provide dosing for any compound or therapy, and several topics discussed are investigational or lack outcome trials. Use your own clinical judgment and consult primary sources.

    Written by

    Dr. Sanjeev Goel, MD

    Longevity physician with 20+ years of experience in preventative and precision medicine.

    Subscribe
    VIP Community

    Unlock Your Full Potential